

The 14th Annual BioExec Institute Retreat

Wednesday, 21st March - Saturday, 24th March 2018, Eau Palm Beach Resort & Spa, FL

Wednesday, 21 March 2018	
19.00 – 22.00	The Welcome Cocktail Reception (The Breeze Bar, Eau Palm Beach Resort)
Thursday, 22 March 2018	
08.00 – 09.00	Registration (The Ocean Ballroom Foyer) & Group Breakfast (The Ocean Ballroom Terrace)
Group Discussion Sessions (The Ocean Ballroom, Eau Palm Beach Resort)	
09.00 – 09.05	Welcome from The BioExec Institute CEO: Hoda Abou-Jamra
09.05 – 09.15 (10 mins)	Introducing Newcomers: New attendees will be welcomed by the Session Chairperson and invited to introduce themselves to the group.
09.15 – 10.15 (1 hr)	<p>Interactive Panel: The Future of Biotechnology and Life Sciences - Are We at a Tipping Point? <i>As the biotechnology and life sciences sector growth is closely tied to global healthcare expenditures which, in 2018 and successive years, are expected to be fueled by increasing demand from an aging population, healthcare consumerism and the burgeoning prevalence of chronic and communicable diseases, it has made the future of the industry be a bit of an unpredictable conundrum we must all face. This interactive panel will take a look at the current state of affairs in the sector, explore trends and issues impacting market segments and individual organizations and suggest considerations for stakeholders as they seek to grow revenue and market share in 2018 and beyond.</i></p> <p><u>Panellists:</u></p> <ul style="list-style-type: none"> • Panel Chair: Helmut Schuehler, Chairman & CEO, TVM Capital Healthcare • Patrick Anquetil, CEO, Portal Instruments • Fred Frank, Chairman, Evolution Life Science Partners • Ed Mathers, Partner, NEA - New Enterprise Associates • Chris Seaton, SVP, Negotiations, Bayer
10.15 – 10.40 (25 mins)	Social & Refreshment Break
10.40 – 11.40 (1 hr)	<p>Interactive 'Biotech CEO' Panel: A Year In: What Will Today's Government Mean to the Industry? <i>Now that the Trump Administration has been operating for over a year and the effects of BREXIT are starting to be seen throughout the industry, what can the life sciences industry expect from today's governments? In this interactive session we will discuss these impacts that affect Biotech:</i></p> <ul style="list-style-type: none"> • Brexit and EMA move to Amsterdam • FDA – Gottlieb/PDUFA <ul style="list-style-type: none"> - Where do we believe the FDA will enact changes to affect go-to-market strategies • Orphan Drug Designation • Business Model - What works today and will work in the years to come? <ul style="list-style-type: none"> - Private vs Public <p><u>Panel Facilitators:</u></p> <ul style="list-style-type: none"> • Steve Carchedi, CEO, Apexian Pharmaceuticals • Sanjeev Luther, CEO, Rafael Pharmaceuticals
11.40 – 12.00 (20 mins)	Social & Refreshment Break

12.00 – 12.30 (30 mins)	<p>OPEN ROUNDTABLE DISCUSSIONS</p> <p><i>These roundtable sessions are an informal and interactive way to discuss industry issues. Each table holds approximately 11 people and is facilitated by a Moderator, enabling all attendees to provide feedback and input. The discussions take place simultaneously for 30 minutes and the Moderators then give a brief 5-minute synopsis on their table's discussion for the benefit of the other tables.</i></p> <p>TABLE 1: Why Life Sciences Cannot Ignore Big Data in 2018</p> <ul style="list-style-type: none"> Facilitator: Meeta Chatterjee, Head, Strategy, Transactions & Operations, Merck <p>TABLE 2: Crafting New Approaches to Value-Based Therapy Payment Models</p> <ul style="list-style-type: none"> Facilitator: John Brooks, Managing Director, HealthCare Capital <p>TABLE 3: Raising Capital: Now or Later - Determining the Right Time to Raise Capital</p> <ul style="list-style-type: none"> Facilitator: Pascale Witz, CEO, PWH Advisors <p>TABLE 4: Embedding Diversity into Board and Executive Team Recruitment</p> <ul style="list-style-type: none"> Facilitator: Gino Santini, Chairman of the Board, AMAG Pharmaceuticals <p>TABLE 5: Fighting the Opioid Epidemic</p> <ul style="list-style-type: none"> Facilitator: Tbc <p>TABLE 6: The Battle Between Biotech Unicorns</p> <ul style="list-style-type: none"> Facilitator: Tbc
12.30 – 13.00 (30 mins)	<p>OPEN ROUND TABLE SUMMARIES</p> <p>The Session Chairperson will invite each of the Roundtable Moderators to provide a brief 5-minute summary of what their table discussed.</p>
13.00 – 14.30 (1 hr 30 mins)	<p>Lunch (The Ocean Ballroom Terrace)</p>
15.00 – 17.00 (2 hrs)	<p>Group Activities on the Beach</p> <p>A private area has been set up for Retreat guests on the hotel beach for beach activities including group soccer, sailing, body boarding and chair massages.</p>
18.30 – 23.00 (4.5 hrs)	<p>Drinks & Dinner Reception at The Flagler Museum</p> <p>Please meet in The Eau Palm Beach Resort lobby for a group bus transfer that will depart promptly at 18.45pm. Return bus transfers start from 22.45pm.</p>
Friday, 23 March 2018	
08.00 – 09.00	<p>Group Breakfast (The Ocean Ballroom Terrace)</p>
Group Discussion Sessions (The Ocean Ballroom, Eau Palm Beach Resort)	
09.00 – 10.00 (1 hr)	<p>Interactive 'Finance' Panel</p> <p>Tapping into the Public Market's Capital - IPOs and Beyond</p> <p><i>The Biotech IPO activity has slowed down some from the peak we saw in 2015. Companies are taking a deeper dive into the decision-making process, looking at reverse mergers and other alternatives to benefiting from capital in public markets. And now, more than a year after the change in Administration, will the IPO market for 2018 and beyond rise, fall or stay level? In this session, we will look at such things as:</i></p> <ul style="list-style-type: none"> What markers should CEOs watch for to gauge their timing and choices? Understanding practical techniques for getting into public markets Identifying what investors are expecting to see in order to "win" their support <p><u>Panellists:</u></p> <ul style="list-style-type: none"> Panel Chair: David Schechner, Managing Director, Baird Marina Bozilenko, Managing Director, William Blair Bjorn Koch, SVP, UBS Spike Loy, Managing Director, BVF Partners

10.00 – 11.00 (1 hr)	<p>Interactive Panel: Pharma-Biotech Partnerships: Creative Approaches to Doing the Deal <i>The relationship between pharma and biotech is mature and mutually dependent. However, there is no question that research and development partnerships between big pharma and the biotech sector are a vital component to bringing new medicines to the market. In this interactive panel we will take a look at the trade-offs and opportunities of bringing together big pharma and small biotechs. We will include a look at various option type of deals and novel deal structures.</i></p> <p><u>Panellists A - Z by surname:</u></p> <ul style="list-style-type: none"> • Panel Chair: Sandy Zweifach, President & CEO, Nuvelution Pharma • Bharatt Chowrira, President & Chief of Business and Strategy, PureTech Health • Rekha Hemrajani, COO, FLX Bio
11.00 – 11.30 (30 mins)	<p>Refreshment Break & Room Checkout: As well as a coffee break, this is also an opportunity for attendees departing today to check out of their rooms in time for the 12pm deadline. We recommend that any luggage be stored safely with the concierge until your departure.</p>
11.30 – 12.30	<p>Group Conversation: <i>During this interactive conversation our Facilitators will lead the entire room a robust discussion on the idea of “Right-to-Try” allowing all participants the opportunity to share opinions, ideas, thoughts and best practices.</i></p> <p>Right to Try: A Healthcare Reform that can Save Lives? <i>Currently patients have two main options to access experimental therapies that may treat their conditions but have not yet been approved by the FDA. Is “Right-To-Try” legislation the answer that can save lives? In this interactive session, dialogue will revolve around issues such as:</i></p> <ul style="list-style-type: none"> • What are the concerns with Right-to-Try Laws? • Will pharma participate? • What drugs and how promising? • What doctors will use this? • Which patients can/should qualify? • Who pays? • What alternatives are there to Right-to-Try Laws? <p>Conversation Facilitators:</p> <ul style="list-style-type: none"> • Graham Brazier, VP, Business Development, Bristol-Myers Squibb Co. (tbc) • Todd Smith, CEO, Novum Pharma
12.30 – 14.00 (1hr 30 mins)	<p>Lunch (The Ocean Ballroom Terrace)</p>
Golf: 13.30 – 18.00 Beach: 15.00 – 17.00	<p>Group Activities</p> <p>Option 1 - On the Beach: A private area has been set up for Retreat guests on the hotel beach for beach activities including volleyball, sailing, body boarding and chair massages.</p> <p>Option 2 – Golf at PGA National (Palmer Course): Please be in the hotel foyer by 13.30 promptly for a transfer to the golf course. Tee times start from 14.39. Golf sponsored by: Jupiter Orphan Therapeutics</p> <p>Our afternoon of golf will include a <i>chip-off</i> and <i>closest to the pin</i> to decide the lucky winners of these top of the range golf clubs donated by Jupiter Orphan Therapeutics:</p> <ul style="list-style-type: none"> • A Callaway Epic 10.5° Driver with a regular flex shaft (Right Handed) • An Odyssey O-Works 2-Ball Putter with a Super Stroke grip (Right Handed)
19.45 – 23.00	<p>Informal Dinner at The Flagler Steakhouse at The Breakers, Palm Beach</p> <p>Please meet in The Eau Palm Beach Resort lobby for a group bus transfer that will depart at 19.45pm. Return bus transfers start from 22.45pm.</p> <p>A separate transfer for the golfers will depart at 20.15pm.</p>
Saturday, 24 March 2018	
10.00 – 11.00 (1 hr)	<p>Breakfast (Angle Restaurant)</p>